Univariate and multivariate analysis of progression-free and overall survival according to patients' characteristics
|
Characteristic | Univariate analysis | Multivariate analysis | ||||
| P value progression- free survival | P value overall survival | Progression-free survival | Overall survival | |||
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| CRS | 0.027 | 0.048 | ||||
| CRS1 | 1.00 | 1.00 | ||||
| CRS2 | 0.55 (0.28 to 1.10) | 0.092 | 0.71 (0.29 to 1.78) | 0.474 | ||
| CRS3 | 0.35 (0.20 to 0.61) | < 0.0001 | 0.38 (0.18 to 0.82) | 0.013 | ||
| Age | 0.826 | 0.323 | 1.00 (0.98 to 1.02) | 0.877 | 1 (0.99 to 1.04) | 0.303 |
| FIGO stage | 0.539 | 0.266 | ||||
| IIIC | 1.00 | 1.00 | ||||
| IV | 1.37 (0.74 to 2.52) | 0.316 | 1.74 (0.79 to 3.84) | 0.171 | ||
| Number of NACT cycles | 0.604 | 0.911 | 1.08 (0.91 to 1.29) | 0.362 | 1.03 (0.81 to 1.33) | 0.770 |
*χ2 of progression-free survival Cox model is 13.67, χ2 of overall survival Cox model is 8.87.
CRS, chemotherapy response score; FIGO, International Federation of Obstetics and Gynecology; NACT, neoadjuvant chemotherapy.